Literature DB >> 15388252

Non-peptide antigens activating human Vgamma9/Vdelta2 T lymphocytes.

Mary Poupot1, Jean-Jacques Fournié.   

Abstract

Various non-peptidic ligands which specifically activate most of circulating human Vgamma9/Vdelta2 T lymphocytes are now known. Most of these are so-called phosphoantigens and directly trigger the Vgamma9/Vdelta2 TCR expressing cells, without need for MHC-restricted presentation molecules. Although some potent phosphoantigens currently involved in clinical trials are chemically-synthesized molecules, most of the natural antigens were isolated from microbial cultures. The structures and biosynthesis of phosphoantigens are reviewed here and the possible physiological significance of their recognition by gammadelta T lymphocytes is discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15388252     DOI: 10.1016/j.imlet.2004.06.013

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  13 in total

Review 1.  Role of apolipoproteins in gammadelta and NKT cell-mediated innate immunity.

Authors:  Eric Champagne; Laurent O Martinez; Pierre Vantourout; Xavier Collet; Ronald Barbaras
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

2.  Avoidance of On-Target Off-Tumor Activation Using a Co-stimulation-Only Chimeric Antigen Receptor.

Authors:  Jonathan Fisher; Pierre Abramowski; Nisansala Dilrukshi Wisidagamage Don; Barry Flutter; Anna Capsomidis; Gordon Weng-Kit Cheung; Kenth Gustafsson; John Anderson
Journal:  Mol Ther       Date:  2017-03-22       Impact factor: 11.454

Review 3.  Eradicating HIV-1 infection: seeking to clear a persistent pathogen.

Authors:  Nancie M Archin; Julia Marsh Sung; Carolina Garrido; Natalia Soriano-Sarabia; David M Margolis
Journal:  Nat Rev Microbiol       Date:  2014-11       Impact factor: 60.633

4.  Modulation of γδ T-cell activation by neutrophil elastase.

Authors:  Nadia Yasmín Towstyka; Carolina Maiumi Shiromizu; Irene Keitelman; Florencia Sabbione; Gabriela Verónica Salamone; Jorge Raúl Geffner; Analía Silvina Trevani; Carolina Cristina Jancic
Journal:  Immunology       Date:  2017-10-05       Impact factor: 7.397

Review 5.  γδ T cell receptor ligands and modes of antigen recognition.

Authors:  Eric Champagne
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2011-02-06       Impact factor: 4.291

6.  Engineering γδT cells limits tonic signaling associated with chimeric antigen receptors.

Authors:  Jonathan Fisher; Roshan Sharma; Dilu Wisidagamage Don; Marta Barisa; Marina Olle Hurtado; Pierre Abramowski; Lucy Porter; William Day; Roberto Borea; Sarah Inglott; John Anderson; Dana Pe'er
Journal:  Sci Signal       Date:  2019-09-10       Impact factor: 8.192

7.  HMGB1 and cord blood: its role as immuno-adjuvant factor in innate immunity.

Authors:  Alessandra Ciucci; Ida Gabriele; Zulema A Percario; Elisabetta Affabris; Vittorio Colizzi; Giorgio Mancino
Journal:  PLoS One       Date:  2011-08-22       Impact factor: 3.240

8.  Regulatory activity of azabisphosphonate-capped dendrimers on human CD4+ T cell proliferation enhances ex-vivo expansion of NK cells from PBMCs for immunotherapy.

Authors:  Damien Portevin; Mary Poupot; Olivier Rolland; Cédric-Olivier Turrin; Jean-Jacques Fournié; Jean-Pierre Majoral; Anne-Marie Caminade; Remy Poupot
Journal:  J Transl Med       Date:  2009-09-24       Impact factor: 5.531

9.  Vγ9Vδ2 T Cells Activation Through Phosphoantigens Can Be Impaired by a RHOB Rerouting in Lung Cancer.

Authors:  Chloé Laplagne; Sarah Meddour; Sarah Figarol; Marie Michelas; Olivier Calvayrac; Gilles Favre; Camille Laurent; Jean-Jacques Fournié; Stéphanie Cabantous; Mary Poupot
Journal:  Front Immunol       Date:  2020-07-07       Impact factor: 7.561

10.  Self-activation of Vγ9Vδ2 T cells by exogenous phosphoantigens involves TCR and butyrophilins.

Authors:  Chloé Laplagne; Laetitia Ligat; Juliet Foote; Frederic Lopez; Jean-Jacques Fournié; Camille Laurent; Salvatore Valitutti; Mary Poupot
Journal:  Cell Mol Immunol       Date:  2021-06-28       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.